title: GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
abstract: The gastrointestinal hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) strongly stimulate insulin release. Despite their high N-terminal sequence similarity, GLP-1 does not bind to the GIP receptor and vice versa. To characterize the domains required for interaction of the peptide ligands with their specific receptors, we performed displacement studies with various synthetic GLP-1/GIP hybrid peptides on RINm5F insulinoma cells. Displacement of 125I-GIP and 125I-GLP-1 was measured using GLP-1/GIP chimeras which comprised GIP and GLP-1 sequences at different positions. The binding affinity to the GLP-1 receptor was found to be sensitive to GIP-like exchanges in the N-terminal 22 amino acids as well as in positions 13 and 15 (loss of affinity 280-fold to more than 1000-fold). C-terminal substitution of the GLP-1 sequence by GIP diminished the affinity towards the GLP-1 receptor only 20-fold. All hybrid peptides investigated showed minimal binding affinity for the GIP receptor, indicating that the entire GIP-sequence (1-31) is important for receptor recognition. These findings provide insight into the structural requirements for the specific interaction of two important insulinotropic peptides with their specific receptors.
authors.affiliation: I. Department of Medicine, Christian-Albrechts-University, Kiel, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Gallwitz
authors.forename: M
authors.initials: M
authors.lastname: Witt
authors.forename: C
authors.initials: C
authors.lastname: Morys-Wortmann
authors.forename: U R
authors.initials: UR
authors.lastname: Fölsch
authors.forename: W E
authors.initials: WE
authors.lastname: Schmidt
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002700:Chloramines / Q000737:chemistry; D000242:Cyclic AMP / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism*; D005765:Gastrointestinal Agents / Q000032:analysis / Q000378:metabolism*; D005934:Glucagon / Q000032:analysis / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D007202:Indicators and Reagents / Q000737:chemistry; D007340:Insulinoma / Q000378:metabolism; D007457:Iodine Radioisotopes; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000032:analysis / Q000378:metabolism*; D011498:Protein Precursors / Q000032:analysis / Q000378:metabolism*; D011869:Radioligand Assay; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000378:metabolism*; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D013329:Structure-Activity Relationship; D014105:Tosyl Compounds / Q000737:chemistry; D014407:Tumor Cells, Cultured
chemical_list: D002700:Chloramines; D005765:Gastrointestinal Agents; D007202:Indicators and Reagents; D007457:Iodine Radioisotopes; D010446:Peptide Fragments; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D014105:Tosyl Compounds; C016300:chloramine-T; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000242:Cyclic AMP